this is taken from hairlosscure2020 website but is valuable to all of us... what do yo guys think?
In any event the whole reason for this post is that today came news that Aclaris Therapeutics was buying Vixen Pharmaceuticals (Dr. Angela Christiano and Columbia University affiliated company). At first, when I read a one paragraph news alert summary of this acquisition, I did not think much of this development since I had been to Aclaris’ website in the past and remember reading that they only deal with Alopecia Areata related drugs.
However, I then read a lengthier article about this latest acquisitionand some things (see below in red font) clearly stood out:
“As a result of this transaction, Aclaris acquired worldwide rights to intellectual property licensed to Vixen by Columbia University covering the use of certain Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata, androgenetic alopecia and other dermatological conditions.â€
“The acquisition of the Vixen intellectual property and the licensed JAKPharm and Key Organics compounds solidifies Aclaris’ presence in the JAK inhibitor space and allows us to broaden our focus in hair loss to include androgenetic alopecia, often referred to as female or male pattern baldness,†said Neal Walker, President and Chief Executive Officer of Aclaris. [hair transplant: Commentator Julian for pointing out that Mr. Walker is also CEO of Follica].
“We are delighted to enter into this agreement with Aclaris for the development of JAK inhibitors for alopecia areata, androgenetic alopecia, and other hair loss disorders,†said Dr. Christiano.â€
In any event the whole reason for this post is that today came news that Aclaris Therapeutics was buying Vixen Pharmaceuticals (Dr. Angela Christiano and Columbia University affiliated company). At first, when I read a one paragraph news alert summary of this acquisition, I did not think much of this development since I had been to Aclaris’ website in the past and remember reading that they only deal with Alopecia Areata related drugs.
However, I then read a lengthier article about this latest acquisitionand some things (see below in red font) clearly stood out:
“As a result of this transaction, Aclaris acquired worldwide rights to intellectual property licensed to Vixen by Columbia University covering the use of certain Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata, androgenetic alopecia and other dermatological conditions.â€
“The acquisition of the Vixen intellectual property and the licensed JAKPharm and Key Organics compounds solidifies Aclaris’ presence in the JAK inhibitor space and allows us to broaden our focus in hair loss to include androgenetic alopecia, often referred to as female or male pattern baldness,†said Neal Walker, President and Chief Executive Officer of Aclaris. [hair transplant: Commentator Julian for pointing out that Mr. Walker is also CEO of Follica].
“We are delighted to enter into this agreement with Aclaris for the development of JAK inhibitors for alopecia areata, androgenetic alopecia, and other hair loss disorders,†said Dr. Christiano.â€